Novel treatment concepts for graft-versus-host disease
Open Access
- 5 January 2012
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 119 (1), 16-25
- https://doi.org/10.1182/blood-2011-08-339465
Abstract
Acute and chronic graft-versus-host disease (GVHD) are potentially lethal complications after stem cell transplantation (SCT). Steroids are the appropriate first-line treatment for both. However, if patients do not adequately benefit from steroid therapy, mortality is high and standardized treatment algorithms are lacking. This is mainly because of limited data from prospective, randomized clinical trials. In addition, most of the available treatment options only induce clinical benefits in a limited proportion of patients. Thus, there is an urgent clinical need to develop more potent immunosuppressive treatment strategies for patients suffering from acute or chronic steroid-refractory GVHD while maintaining the graft versus tumor effect to avoid a potential rise in relapse-related mortality. The increasing knowledge about host- as well as donor-derived variables favoring GVHD development and the increasing armamentarium of immune-modulatory agents entering preclinical and clinical research will probably allow more effective treatment of GVHD in the future. This review describes novel developments in the treatment of steroid-refractory GVHD, with a special focus on the rationale behind promising pharmacologic compounds or up-coming cellular therapies.This publication has 105 references indexed in Scilit:
- A Requisite Role for Induced Regulatory T Cells in Tolerance Based on Expanding Antigen Receptor DiversityImmunity, 2011
- An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell ResponsivenessImmunity, 2010
- Mesenchymal stem cell as salvage treatment for refractory chronic GVHDBone Marrow Transplantation, 2010
- Concise Review: Hitting the Right Spot with Mesenchymal Stromal CellsThe International Journal of Cell Cloning, 2010
- Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor GrowthJNCI Journal of the National Cancer Institute, 2010
- NOD2 regulates hematopoietic cell function during graft-versus-host diseaseThe Journal of Experimental Medicine, 2009
- Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cellsBone Marrow Transplantation, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing mediumBone Marrow Transplantation, 2008
- HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimenProceedings of the National Academy of Sciences of the United States of America, 2008